# Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

> **NCT07527975** · — · ENROLLING_BY_INVITATION · sponsor: **Rocket Pharmaceuticals Inc.** · enrollment: 14 (estimated)

## Conditions studied

- Fanconi Anemia

## Interventions

- **BIOLOGICAL:** RP-L102

## Key facts

- **NCT ID:** NCT07527975
- **Lead sponsor:** Rocket Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-02-01
- **Primary completion:** 2038-05
- **Final completion:** 2038-05
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527975, "Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07527975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*